Week Ending April 18, 2022

Adebrelimab Improves PFS, OS in Extensive-Stage Small Cell Lung Cancer
“Adebrelimab plus chemotherapy improved survival outcomes over chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from a phase 3 trial presented at the AACR Annual Meeting 2022.”

COVID-19 caused millions of missed cancer screenings; how will oncology community respond?
“Although much remains unknown about the impact of COVID-19 on people with cancer, the impact on screening is becoming clearer.”

Neoadjuvant Nivolumab a ‘New Standard’ in Lung Cancer
— “Another quantum leap in lung cancer therapy,” expert says
NEW ORLEANS – “The addition of the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy substantially improved event-free survival (EFS) in patients with operable non-small cell lung cancer (NSCLC), the phase III CheckMate 816 trial showed.”

Einstein Researchers Explain Why Some Smokers Get Lung Cancer, And Others Don’t
“Not all smokers develop lung cancer. Einstein researchers have found a new way to identify smokers who at higher risk for lung cancer.”

Should People With HIV Be Prioritized for Lung Cancer Screening?
“A small Spanish study suggests that screening people living with HIV for lung cancer results in a high rate of diagnosis.”

Lumakras® (Sotorasib) Codebreak 100 Study Shows Two-Year Overall Survival Of 32.5% in Patients With Kras G12c-Mutated Advanced Non-Small Cell Lung Cancer
“Amgen today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib)*.”

Immunotherapy may boost survival for lung cancer patients
“Lifelong smoker Mike James had quit the habit for nearly three years when, through fluky circumstances, he found out that he had a small tumor in his right lung.”

Revolutionary lung cancer detection tool performs 100th procedure at Freeman
“A revolutionary robotic tool, which helps Freeman Health System doctors detect and treat early-stage lung cancer, recently performed its 100th successful procedure.”

In the Neoadjuvant Setting, Combination Immunotherapy With Durvalumab Is More Effective Than Durvalumab Alone for Early-Stage NSCLC
“Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to research presented by Cascone et al at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract CT011).”

Patients With Lung Cancer and a Genetic Variant Linked to Autoimmune Disease May Be Especially Responsive to Immunotherapy
“A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in patients with non–small cell lung cancer (NSCLC) who experienced an exceptionally high response to anti–PD-1 immunotherapy and a higher rate of immune-related side effects than in a comparable cohort of patients with lung cancer and healthy individuals, according to data presented by Allen et al during the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract 665).”

Dr Davey Daniel on Barriers Limiting Genomic Testing Use in Lung Cancer
“Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.”